The 66th ASH Annual Meeting and Exposition took place from the 7th to the 10th of December, 2024 in San Diego, California.
CML Advocates Network was represented by Catherin Moura, Jan Geissler, Giora Sharf and Gerald Clements who attended the conference and participated in several activities and sessions.
The conference covered key updates in Chronic Myeloid Leukemia (CML) treatment, highlighting new treatment options, treatment-free remission (TFR), and managing side effects of tyrosine kinase inhibitors (TKIs). Some insights include:
- Asciminib is emerging as a superior alternative to traditional TKIs, offering deeper molecular responses and increasing the likelihood of TFR.
- TGRX-678 and olverembatinib show promise in treating resistant CML, particularly in patients with the challenging T315I mutation.
- Studies provided reassuring evidence that brief exposure to TKIs in early pregnancy does not lead to birth abnormalities or worse maternal outcomes.
These findings highlight significant progress in personalized CML treatment, better management of therapy risks, and improved access to TFR strategies worldwide.
We commissioned a report of CML sessions which was written by Patvocates, supported with material graciously provided by iCMLf that summarises the key CML highlights of interest to the patient advocacy community.
Click on an image to enlarge it!
